Matches in Wikidata for { <http://www.wikidata.org/entity/Q90693483> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q90693483 description "clinical trial" @default.
- Q90693483 description "ensayo clínico" @default.
- Q90693483 description "ensayu clínicu" @default.
- Q90693483 description "klinisch onderzoek" @default.
- Q90693483 description "клінічне випробування" @default.
- Q90693483 name "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 name "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 type Item @default.
- Q90693483 label "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 label "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 prefLabel "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 prefLabel "Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer" @default.
- Q90693483 P1132 Q90693483-6C1B0787-5CE7-4AAD-A03D-3AE21D9D51D2 @default.
- Q90693483 P1476 Q90693483-EFD28248-7D52-478F-9AD1-7486E1093647 @default.
- Q90693483 P1813 Q90693483-C22747F7-6E86-4449-A5D1-1F33C53910D5 @default.
- Q90693483 P2899 Q90693483-08F32353-E439-4B9D-8022-8D3C77DE2D5E @default.
- Q90693483 P3098 Q90693483-E43F226F-47A1-441C-9DFD-0628CE23DA12 @default.
- Q90693483 P31 Q90693483-CC8891F0-CE62-475E-B815-E5DC4382B912 @default.
- Q90693483 P4135 Q90693483-98AE7154-D5AC-4BA5-9E30-837D0561B79F @default.
- Q90693483 P4844 Q90693483-38ED76FC-F237-47F1-BFBA-1524BD58B915 @default.
- Q90693483 P4844 Q90693483-43385A45-9E51-4D74-AD2B-52C7AEC01BAA @default.
- Q90693483 P4844 Q90693483-78437374-422D-4694-934C-40C7F48E62AE @default.
- Q90693483 P4844 Q90693483-F12C191B-159D-45E9-826B-6679996D1B65 @default.
- Q90693483 P580 Q90693483-BC0F92F3-9E7D-4CC9-9389-7E2543FCD3D1 @default.
- Q90693483 P582 Q90693483-522D2CE0-0D4D-4C52-940E-23B3DA6210A9 @default.
- Q90693483 P6099 Q90693483-7BD680AF-0ED2-4023-A716-AABF7886928C @default.
- Q90693483 P8363 Q90693483-02D9FD08-B376-419E-B5D7-034587CA9DA3 @default.
- Q90693483 P1132 "+493" @default.
- Q90693483 P1476 "A Phase 3, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Anti-HER2 Therapy Plus Fulvestrant or Capecitabine in First-line Treatment of Women With HR+, HER2+, Non-visceral Metastases, Stage IV Breast Cancer" @default.
- Q90693483 P1813 "FAVOR" @default.
- Q90693483 P2899 "+18" @default.
- Q90693483 P3098 "NCT04337658" @default.
- Q90693483 P31 Q30612 @default.
- Q90693483 P4135 "+75" @default.
- Q90693483 P4844 Q1998021 @default.
- Q90693483 P4844 Q412616 @default.
- Q90693483 P4844 Q420207 @default.
- Q90693483 P4844 Q5508491 @default.
- Q90693483 P580 "2020-07-01T00:00:00Z" @default.
- Q90693483 P582 "2024-04-30T00:00:00Z" @default.
- Q90693483 P6099 Q42824827 @default.
- Q90693483 P8363 Q78089383 @default.